What Exactly is an RNA Foundry?
Think of a high-tech, specialised factory, but instead of computer chips, it produces molecules central to life: RNA. The term 'foundry' implies a facility designed for rapid, customisable production. PopVax's RNA Foundry in Hyderabad is an integrated
site that combines research, development, and manufacturing under one roof. Its core purpose is to dramatically shorten the time it takes to go from a new idea for a medicine to a finished product ready for clinical trials. The facility is specifically equipped to handle messenger RNA (mRNA), the same technology that powered the revolutionary COVID-19 vaccines. By integrating every step—from designing an RNA sequence using AI to packaging it in lipid nanoparticles (LNPs) for delivery into the body—the foundry aims to create a seamless and swift production line for next-generation therapies.
The Power of Personalised Medicine
The new foundry's primary focus is on one of the most exciting frontiers in healthcare: personalised medicine. Instead of a one-size-fits-all approach, this field tailors treatments to an individual's unique genetic makeup. This is especially transformative for cancer treatment. Every patient's tumour has a unique set of mutations, which can produce abnormal proteins called neoantigens. PopVax uses artificial intelligence and genetic sequencing to identify these neoantigens in a patient's tumour. The RNA Foundry then manufactures a custom mRNA vaccine designed to teach that specific patient's immune system to recognise and attack only the cells bearing those markers. This bespoke approach holds the promise of creating highly targeted therapies with fewer side effects. PopVax and its partner Stochastic Sciences plan to produce over 100 patient-specific cancer vaccines in the next year at the Hyderabad facility.
Why Hyderabad is the Perfect Hub
The decision to establish this cutting-edge facility in Hyderabad is no coincidence. The city is firmly established as India's premier life sciences and pharmaceutical hub, often called the 'Vaccine Hub of India'. It is home to Genome Valley, a sprawling cluster hosting over 200 biotech and pharma companies, including the R&D centres of six of the world's top ten life sciences firms. The city accounts for roughly one-third of India's total pharmaceutical production and a significant portion of its exports. This ecosystem provides a rich talent pool, robust infrastructure, and a network of research institutions and super-speciality hospitals crucial for clinical trials. The presence of industry giants and a supportive policy environment have turned Hyderabad into a magnet for global investment in healthcare innovation, making it the ideal ground for a facility like the RNA Foundry.
PopVax's Vision and Global Ambition
Founded in 2021, PopVax is a 'full-stack' biotech company, meaning it handles everything from AIndriven design to manufacturing inhouse. Its stated mission is to save one million lives each year through the development of novel vaccines and therapies. The company is not only focused on personalised cancer treatments but also on creating vaccines for challenging infectious diseases like Hepatitis C, TB, and malaria. The technology and processes used at the RNA Foundry are the same ones behind PopVax's broadly protective COVIDndriven vaccine candidate, which entered clinical trials in Australia in August 2026. Notably, their delivery platform allows for the vaccine to be stored in a standard refrigerator, overcoming the ultrandcold chain challenges that limited early mRNA vaccines. With backing from prominent funders like the Gates Foundation and Vitalik Buterin's Balvi Fund, PopVax aims to leapfrog existing drug development models from its base in India.
